注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Celyad Oncology SA,(原名:Celyad SA)是一家比利时公司。该公司是一家临床阶段的生物技术公司,致力于发现和开发用于癌症的嵌合抗原受体T细胞(CAR T)疗法。该公司为患有血液系统恶性肿瘤和实体瘤的癌症患者开发同种异体和自体CAR T细胞疗法候选药物。该公司的产品CYAD-101是基于细胞活化性(NKG2D)受体的CAR T,它结合了非基因编辑的异基因T细胞抗原受体抑制分子(TIM)技术,用于治疗难治性转移性结直肠癌(mCRC)。它还开发了基于短发夹核糖核酸(shRNA)的异基因CAR T候选物CYAD-211,用于治疗复发或难治性多发性骨髓瘤(r/r MM)。它的自体CAR T专营权正在评估NKG2D受体CAR T候选CYAD-02,用于治疗复发或难治性急性髓细胞白血病(r/r AML)和骨髓增生异常综合症(MDS)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Michel E. J. Lussier | 68 | 2007 | Co-Founder, Interim CEO & Executive Director |
Marco L. Davila | - | 2016 | Member of Scientific Advisory Board |
Serge Goblet | 66 | 2008 | Non-Executive Director |
Hinrich Abken | - | 2016 | Member of Scientific Advisory Board |
Marina Udier Blagovic | - | 2020 | Independent Director |
Hilde Windels | 59 | 2017 | Independent Chairwoman of the Board |
Dominic G. Piscitelli | 49 | 2020 | Independent Director |
Christopher LiPuma | - | 2022 | Non-Executive Director |
Margo R. Roberts | 69 | 2018 | Member of Scientific Advisory Board |
Gerry Graham | - | - | Member of Scientific Advisory Board |
Ann Ager | - | - | Member of Scientific Advisory Board |
Ami Patel Shah | - | 2021 | Non-Executive Director |
Jean-Christophe Marine | - | - | Member of Scientific Advisory Board |
Andrea Gothing | - | 2024 | Non-Executive Director |
John Campbell | - | - | Member of Scientific Advisory Board |
Jonathan James | - | 2024 | Non-Executive Director |
Sage Mandel | - | 2024 | Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核